chrisvoncsefalvay/vaers-outcomes huggingface dataset:
This initial spontaneous report was received from a healthcare worker referring to a patient of unknown age and gender. There was no pertinent medical history or drug allergies/drug reactions reported. The reported stated that on 25-AUG-2015, the patient was vaccinated with an expired dose of (Oka/Merck) VARIVAX injection (lot # J006694 with expiration date 30-MAY-2015; strength, dose and route were not provided). There was no concomitant medication reported. No product quality complaint was involved and no adverse experiences were reported. Additional information has been requested.
Fever; injection site pain (redness and swelling); extreme back and muscle pain; excessive fatigue; pressure in my head, but different from a normal headache causing my eye to turn bloodshot red. Nausea. Vaginal bleeding. My period was not due. I began to bleed within 72 hours of vaccination with increased muscle pain.
Patient was given a Hep A peds vaccine and should have received Hep A adult. Patient needs another dose for this to be effective.
Patient received moderna vaccine on 2/9/21, 3/9/21, and 11/5/21. Presented to ER on 7/12/22 and found to be COVID positive. presents to ER after syncopal episode. She was in a meeting when she became woozy and passed out. There were some witnesses, no seizre like activity noted. Patient denies feeling palpiations or sob prior to the episode. She lost consciousness for a brief period. When she woke up she was not confused. Per the daughter, patient has had what sound like vasovagal episodes while giving blood in the past. Patient had a bout of emesis when she woke up as well. She denies current nausea, abd pain, cp, sob or focal neuro s/s. Admitted and not placed on any specific COVID19 treatments. Discharged on 7/14/22
Developed  DVT in left calf causing me to get a bloody filter in my  Vena Cava and put on blood thinners the rest of my life
Doses administered after more than 1 temperature excursion during a period of 33 weeks on 2021; Doses administered after more than 1 temperature excursion during a period of 33 weeks on 2021; This spontaneous case was reported by an other health care professional and describes the occurrence of POOR QUALITY PRODUCT ADMINISTERED (Doses administered after more than 1 temperature excursion during a period of 33 weeks on 2021) and PRODUCT TEMPERATURE EXCURSION ISSUE (Doses administered after more than 1 temperature excursion during a period of 33 weeks on 2021) in a 54-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 007C21A) for COVID-19 vaccination.     No Medical History information was reported.    On 28-Apr-2021 at 4:24 PM, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) .5 milliliter. On 28-Apr-2021 at 4:24 PM, the patient experienced POOR QUALITY PRODUCT ADMINISTERED (Doses administered after more than 1 temperature excursion during a period of 33 weeks on 2021). On an unknown date, the patient experienced PRODUCT TEMPERATURE EXCURSION ISSUE (Doses administered after more than 1 temperature excursion during a period of 33 weeks on 2021). At the time of the report, POOR QUALITY PRODUCT ADMINISTERED (Doses administered after more than 1 temperature excursion during a period of 33 weeks on 2021) and PRODUCT TEMPERATURE EXCURSION ISSUE (Doses administered after more than 1 temperature excursion during a period of 33 weeks on 2021) outcome was unknown.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   Age of patient was reported as 54.27. No concomitant medications were reported. On 28-Apr-2021 at 09:00 A.M., the temperature recorded was 33 degree Fahrenheit and vial was initially moved to the fridge on 19-Apr-2021 and beyond use date was 19-May-2021. Product moved to clinic on 28-Apr-2021.  Vial was stored on cooler 1, on 28-Apr-2021, Excursion duration At 9 AM: 33, 10 AM: 36, 11 AM: 40, 12 AM: 41 1PM: 41, 2 PM : 39, 3 PM: 41, 4 PM: 40.  Vial was in cooler storage and was not in frozen storage during high-pace COVID-19 vaccination at around 2021. Vials were only punctured right before administration. Vaccines were not frozen at time of administration. It was reported that each time a vial was put into a cooler, sometimes there was a period of 1 hour or 1 hour and a half approximately, when temperature data logger registered a temperature of 34- or 35-degree Fahrenheit. Temperature recordings were taken using a traceable temperature monitor at every hour. No treatment medications were reported.   This case was linked to MOD-2022-566976 (Patient Link).
numbness , tingling and occ. pain on all fingertips,  both hands,  no treatment so far.
Pt vaccinated with MMR developed joint stiffness & soreness, slight bruising at inject site, rash which was described as itchy, no redness or swelling.
Within an hour symptoms of burning sensation in my lungs resulted in going to the ER with pneumonia and a collapsed lung within 72 hours of the injection
PATIENT WAS WALKING OUT TO HER CAR WITH HER FATHER AFTER GETTING HER SHOT AND BEGAN TO FEEL LIGHTHEADED. SHE PASSED OUT ON THE PAVEMENT AND WAS UNCONSCIOUS FOR APPROXIMATELY 3 MINUTES. HER FATHER WHO IS A NURSE ENSURED SHE WAS SUPPORTED. SHE RECOVERED SHORTLY AFTER AND REPORTS THAT SHE IS FEELING OK NOW. PATIENT DID NOT WAIT THE 15 MINUTES RECOMMENDED AFTER RECEIVING HER VACCINATION BEFORE LEAVING THE STORE.
Patient received her vaccination at 5:15. Patient did state she has a history of fainting after vaccination when sitting up. Ems on site able to lie down to receive vaccination. Patient continued to lie down until 15 min after then transferred her walking to monitoring station. EMS on hand monitoring. B/p/112/70 100 Pulse ox, 88P. While patient sitting in monitoring station began to feel faint was able to lie down with help of EMS and started feeling better. Patient was able to drink juice and stated she started to feel better . Declined further treatment from EMS. Patient left after 15 more min of monitoring. Gait stable talking with no difficulty.
Within 48 hours of second shot, I was having trouble moving my feet.  I was walking on a tread mill and they didn't seem to want to "work".  I waited a couple of days and it seemed each day the weakness slowly progressed up my legs.  The weakness stopped at my waist after about 5 days.  I had trouble walking and couldn't stand for very long and was very fatigued.
At 1620 patient complains of tongue swelling sensation. BENADRYL 25 mg PO given to patient right away. At 1630 patient complains of tongue swelling is getting worse. EPIPEN 0.3 mg IM given to patient in his right leg. Patient is monitored closely x 40 min. Vitals are checked repeatedly and remain stable. Symptoms completely resolve. Patient is released into the care of his wife.
When I woke up on June 13, the morning after I received my shingles vaccine, I felt very tired and weak. I had no other symptoms but barely managed to take a shower and eat a little breakfast. I went straight to the couch and slept until noon. I tried to eat lunch but could not. I was worried and called the pharmacist who gave me the shot but she said not to worry if I did not have fever.  Back to sleep until about 3:00 p.m. when I woke up and felt better. By then I felt normal and had no other symptoms afterward. When I had the booster vaccine on Oct. 15, the same symptoms occurred but tiredness/weakness was much worse and I could not eat all day - food made me nauseated and I felt like I had been hit by a truck! I stayed on the couch that day until 8:00 p.m. when I began to feel better. By then I was back to normal and felt fine with no other symptoms. I would go through these symptoms again to avoid having shingles but it was not pleasant.
fever / high of 103 , chills, severe body ache and headache, fatigue, lose of appetite. The shot was on Sunday and I felt fine.  Woke up sick with fever and body aches Monday morning.  Fever was controlled by Tylenol, which lasted Monday Tuesday and Wednesday.  Thursday Feb 18 my fever is showing 100.8  but am feeling improvement with body aches and chills. Soreness at site of injection.
sore arm; This spontaneous case was reported by a physician and describes the occurrence of PAIN IN EXTREMITY (sore arm) in a 73-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 036A21A and 029L20A) for COVID-19 vaccination.     No Medical History information was reported.   On 08-Feb-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 08-Mar-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On 08-Mar-2021, the patient experienced PAIN IN EXTREMITY (sore arm). At the time of the report, PAIN IN EXTREMITY (sore arm) outcome was unknown.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   Action taken with mRNA 1273 in response to event was not applicable.  No concomitant medications reported.  No treatment medications were provided
196 patients received 0.25mL of Moderna Covid-19 Vaccine, Bivalent; No adverse event; This spontaneous case was reported by an other health care professional and describes the occurrence of UNDERDOSE (196 patients received 0.25mL of Moderna Covid-19 Vaccine, Bivalent) and NO ADVERSE EVENT (No adverse event) in an adult patient of an unknown gender who received mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) for COVID-19 prophylaxis.     No Medical History information was reported.    On an unknown date, the patient received dose of mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (unknown route) 1 dosage form. On an unknown date, the patient experienced UNDERDOSE (196 patients received 0.25mL of Moderna Covid-19 Vaccine, Bivalent) and NO ADVERSE EVENT (No adverse event). At the time of the report, UNDERDOSE (196 patients received 0.25mL of Moderna Covid-19 Vaccine, Bivalent) and NO ADVERSE EVENT (No adverse event) outcome was unknown.        The action taken with mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (Unknown) was unknown.   For mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (Unknown), the reporter considered NO ADVERSE EVENT (No adverse event) to be not related. No further causality assessment was provided for UNDERDOSE (196 patients received 0.25mL of Moderna Covid-19 Vaccine, Bivalent).    No concomitant medication was reported. No treatment medication was reported.   Most recent FOLLOW-UP information incorporated above includes: On 27-Dec-2022: Live significant follow up: Added age group and updated narrative.
Patient inadvertently received 2 Pfizer Bivalent Booster Covid Vaccines. First on 10/31/2022 Second on 11/29/2022.  Patient reported small headache the day after the second booster vaccine, no headache today 12/01/22 and feels fine.
Patient received Fluzone HD immunization. Patient stated that he had the chills, shakes and felt sore all over after about 5 hours of the admin of the immunization.
She received her second dose on day 6 instead of on the recommended day 7; Case reference number US-BN-2021-002186, initially downloaded on 16-Aug-2021, is a spontaneous case report received from a health professional via health authority (ID: 1371244-1) and concerns a 31-year-old female patient.   The patient's medical history and concomitant medication details were not provided.  On an unspecified date, the patient was vaccinated with the first dose of RabAvert (inactivated rabies virus; batch numbe: ARBA801B), at an unknown dose, administered intramuscularly, for pre-exposure prophylaxis.   On 18-May-2021, reported also as a day six, the patient was vaccinated with the second dose of RabAvert (inactivated rabies virus; batch numbe: ARBA801B), at an unknown dose, administered intramuscularly, for pre-exposure prophylaxis (explicitly coded as Inappropriate schedule of product administration').  On an unspecified date, reported also as day 21, the patient was vaccinated with the third dose of RabAvert (inactivated rabies virus; batch numbe: ARBA801B), at an unknown dose, administered intramuscularly, for pre-exposure prophylaxis.  It was reported that the patient did not experience any adverse event as of the date of this report.  No further information was provided.; Reporter's Comments: Inappropriate schedule of product administration is listed per convention. Reportedly, the patient was vaccinated with the 2nd dose of RabAvert 6 days after receiving the 1st dose, which is considered inappropriate schedule of product administration. The patient did not experience any associated adverse events. Inappropriate schedule of product administration is not related to RabAvert but to human action.; Sender's Comments: Inappropriate schedule of product administration is listed per convention. Reportedly, the patient was vaccinated with the 2nd dose of RabAvert 6 days after receiving the 1st dose, which is considered inappropriate schedule of product administration. The patient did not experience any associated adverse events. Inappropriate schedule of product administration is not related to RabAvert but to human action.
9/20/17: area of erythema on L deltoid that has a 3-4 cm pale red streak from this area toward her L axilla. In center of this area there is an area that is firm and quite tender... no fluctuance.
Patient was walking on a treadmill as he often does.  Patient grabbed left side of chest and said "mama" and collapsed.  He was unconscious and constricted.  Incident happened on 2-5-08 about 5:30.  Mother took to ER at 18:03.  Accuv-102 et EEG.
Burning throughout the body with intensity in the legs, feet, hands, forearm, face and head. Vibration in the legs and feet. Inflammation in the hands and feet, retention of liquids in the feet and hands. It is not removed with anything. They put me on Neurontin 200mg and went up to twice a day. I have no pain, my skin feels like I am burning all the time and I have inflammation.
Chills, followed by fever (103.7 F) and severe sinus-like headaches for about 12 hours
Moderna COVID-19 Vaccine Eua  Moderate soreness and stiffness in injection arm - started 8pm 03/31/2021, reduced to mild 8am 04/02/2021 Fever between 99.6-101 fahrenheit - started 8pm 04/01/2021, reduced to 99.6 but still present as of 9am 04/02/2021 Nausea, loss of appetite - 04/01/2021 Took ibuprofin to manage fever and arm pain at 9pm 04/01/2021, reduced arm pain but fever remained above 100 degrees
430PM pt didn't "feel right," felt weak, vomited, no nausea oral temp 101 degrees headache site sore, swollen, "hurt a little". Episode lasted 3 days.
per mom lt arm swollen; site of inject appears bruised; area below inject site is reddened halfway around arm;
Zoster vaccine was administered to immunocompromised patient. Didn't had any reaction to the vaccine. However, we send patient to Hospital to received Verazig and treated with valacylovir.
I developed a rash that I noticed on Friday(15th)  evening. It became worse as the weekend continued. On Tuesday I started on a steroid and as of the 25th I still have the rash. I discontinued my antibiotic on the 19th in case it was part of the problem. I am still taking benadryl.
Acute knee pain - flare up of osteoarthritis.  Leg weakness that still continues.  High blood pressure.  Trips to ER for ultrasound and xray of the the knee.
Immediate onset of arm pain on side where injection was given.  Then within 2 hours developed headache and upper backache that radiated into front of chest.  Denied any palpatations.  Patient took Advil prior to going to bed to help with  pain in head and back. This discomfort continued from 2pm til  appx 9pm when she went to bed. Restless sleep.  but, awoke in AM without headache or back pain.  Still has an extremely painful  Left upper arm at injection site with some swelling and feels warm to touch.  But, is not red.
Headache, nausea, chills, fever, face started burning around 6:30pm and was bright red. Fever kept getting higher throughout the day. Starting at 100.4 at 1PM and highest was 101.5 at 9:45pm. Body aches. Took alleve to try to break the fever but it didnt break until around 3am on may 10th. May 10th still very tired and and drained. arm is very sore.
Developed a red itchy rash with slight swelling and warm skin at the vaccination site on 3/13/21, 11 days after the vaccine was administered. No side effects at the site immediately after the vaccine except a sore arm for two days.  Today is 3/15/21, and the rash is diminishing.
The pt developed a rash and tightness in chest 1 hour post vax. Taken to ER the following day. The pt continued to complain of tightness in chest, dizziness, back ache, nausea with sporadic vomiting. Seen in ER 2 times.
Pt described itching of ears, top of head, face. Rash noted on arms. Benadryl 50 mg delivered IM right deltoid @11:21am. Symptoms noted by patient at  approximately 11:18 am. Itching has ceased per patient  by  11:50.  Daughter notified, in attendance with patient, will be driving patient home. Advised to contact PCP regarding reaction. Also directed to seek medical attention should symptoms return, or if she feels unwell.
Pain and swelling at injection site, body aches, chills, fatigue (flu like symptoms).
Flu; Initial information received on 23-Jan-2023 regarding an unsolicited valid social media serious case received from a consumer/non-health care professional.  This case involves an unknown age and unknown gender patient who experienced flu after receiving vaccine INFLUENZA VACCINE.  The patient's past medical history, medical treatment(s), vaccination(s) and family history were not provided.   On an unknown date, the patient received a dose of suspect INFLUENZA VACCINE produced by unknown manufacturer (with lot number, dose, strength, formulation, expiry date: not reported) via unknown route in unknown administration site for prophylaxis.  On an unknown date the patient developed a serious flu (influenza) (unknown latency) following the administration of INFLUENZA VACCINE.   Action taken: Not Applicable.  It was not reported if the patient received a corrective treatment for the event (Flu).  At time of reporting, the outcome was Unknown for the event flu.  Based on information previously received, the case classification has been updated from non valid to social media case and the case has been amended
THE PATIENT CAME INTO THE PHARMACY TO ASK ABOUT IF THE PHARMACIST HAD EVER HEARD OF THE SIDE EFFECTS SHE WAS EXPERIENCING WITH THE SHINGLES VACCINE AND IF THEY HAD EVER HEARD OF WHAT SHE EXPERIENCING DUE TO HAVING A LUMPECTOMY FROM PAST BREAST CANCER. PATIENT EXPERIENCED SWELLING IN ARM, REDNESS, AND FACIAL SWELLING. PATIENT ALSO SAID EXPERIENCING A PUTRID TASTE FROM NECK AREA. PATIENT WAS PICKING UP AN ANTIBIOTIC AT THE SAME TIME AND SAID TEETH FEEL LIKE GUMS ARE INCREDIBLY SWOLLEN. PATIENT SAID BELIEVES THIS IS FROM THE SECOND SHINGLES VACCINE
Patient received booster dose of pfizer vaccine (comirnaty) 16 days earlier than the guidelines state (6 months after second dose). Patient received second dose 5/18/2021. Patient received booster dose 11/2/2021. Patient observed in observation area for 15 minutes and denied any symptoms. Patient ambulated out of the facility independently.
This case was reported by a nurse via sales rep and described the occurrence of interchange of vaccine products in a 18-year-old male patient who received BEXSERO for prophylaxis. Previously administered products included TRUMENBA (1st dose received in November 2018). On an unknown date, the patient received BEXSERO. On an unknown date, unknown after receiving BEXSERO, the patient experienced interchange of vaccine products. On an unknown date, the outcome of the interchange of vaccine products was unknown. Additional details were provided as follows: The age at vaccination was not reported. Registered nurse administered a dose of BEXSERO and when the system PRIR had came on, she had noticed that the patient had 1st dose of TRUMENBA not BEXSERO and was administered already, which led to interchange of vaccine products.
01may90 pt vax hepta B. 06may90 pt ex general malaise and weakness which was noted to be similar to influenza, aching joints, aching muscles, and stiff neck.
cellulitis; Erythema; pain; pruritus; sweeling; Fever; chills; headache; myalgias; This is a literature report for the following literature source(s): "COVID Arm: Delayed Hypersensitivity Reactions to SARS-CoV-2 Vaccines Misdiagnosed as Cellulitis.", Journal of Primary Care & Community Health, 2021; Vol:12, DOI:10.1177/21501327211024431.  A 44 year-old female patient received bnt162b2 (COMIRNATY) (Batch/Lot number: unknown) as dose 1, single for covid-19 immunisation. The patient's relevant medical history and concomitant medications were not reported. The following information was reported: CELLULITIS (medically significant), outcome "recovered", described as "cellulitis"; ERYTHEMA (non-serious), outcome "recovered", described as "Erythema"; PAIN (non-serious), outcome "recovered", described as "pain"; PRURITUS (non-serious), outcome "recovered", described as "pruritus"; SWELLING (non-serious), outcome "recovered", described as "sweeling"; PYREXIA (non-serious), outcome "recovered", described as "Fever"; CHILLS (non-serious), outcome "recovered", described as "chills"; HEADACHE (non-serious), outcome "recovered", described as "headache"; MYALGIA (non-serious), outcome "recovered", described as "myalgias". The patient underwent the following laboratory tests and procedures: body temperature: fever. Therapeutic measures were taken as a result of cellulitis, erythema, pain, pruritus, swelling, pyrexia, chills, headache, myalgia.  Follow-up attempts are completed. No further information is expected.; Sender's Comments: As there is limited information in the case provided, the causal association between the event "cellulitis and the suspect drug "BNT162B2" cannot be excluded. The case will be reassessed once new information is available.
front of both thighs looked sunburnt, were beet red; front of both thighs looked sunburnt, were beet red; This is a spontaneous report from a contactable consumer (Patient). A 61-year-old male patient received first dose of BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE, Solution for injection, Lot number: EN6200, expiry date:30Jun2021) via intramuscular at left arm on 24Feb2021 as single dose for COVID -19 Immunization. Patient medical history included Floxin, Penicillin, Prednisone, lacerated cornea and Bee Stings and allergic to chigger bites. He did have to use Prednisone for a lacerated cornea last year and he had to put drops in his eye, but he doesn't have any leftover or anything to provide for the report. Concomitant medication was not reported. No prior vaccination received within 4weeks. On 24Feb2021 patient experienced front of both thighs looked sunburnt, were beet red and thighs looked totally sunburn. He stated that the sunburn didn't hurt. He had no pain. No treatment was given to the event. Outcome of event was recovered on 25Jan2021.  Caller declined to take down the report reference number. No further details were provided or obtained.
Extreme fatigue; This spontaneous case was reported by a consumer and describes the occurrence of FATIGUE (Extreme fatigue) in a 47-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On an unknown date, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced FATIGUE (Extreme fatigue). At the time of the report, FATIGUE (Extreme fatigue) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown Route) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown Route), the reporter did not provide any causality assessments.   Concomitant product use was not provided by the reporter. Treatment information was not provided.